Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, $0.00005 par value
-
Shares outstanding
-
7,182,182
-
Total 13F shares
-
206,710
-
Share change
-
+49,085
-
Total reported value
-
$468,811
-
Price per share
-
$2.27
-
Number of holders
-
29
-
Value change
-
+$407,283
-
Number of buys
-
22
-
Number of sells
-
4
Institutional Holders of BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI) as of Q4 2024
As of 31 Dec 2024,
BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
206,710 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc., HRT FINANCIAL LP, TWO SIGMA SECURITIES, LLC, Ikarian Capital, LLC, MORGAN STANLEY, UBS Group AG, CITIGROUP INC, and OSAIC HOLDINGS, INC..
This page lists
30
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.